https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-12-12 / Front Immunol 2022;13:1080947
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-12-12 / Front Immunol 2022;13:10809472022-12-12 00:00:002022-12-12 00:00:00Derivation and external validation of dendritic cell-related gene signatures for predicting prognosis and immunotherapy efficacy in bladder urothelial carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-06-17 / Pharm Res 2022 Aug;39(8):1851-1866
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-06-17 / Pharm Res 2022 Aug;39(8):1851-18662022-06-17 00:00:002022-06-17 00:00:00Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-19 / Sci Rep 2021 Jul;11(1):14661
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-19 / Sci Rep 2021 Jul;11(1):146612021-07-19 00:00:002021-07-19 00:00:00Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-11-16 / Int J Mol Sci 2020 Nov;21(22)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-11-16 / Int J Mol Sci 2020 Nov;21(22)2020-11-16 00:00:002020-12-07 09:22:05Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-10-26 / Oncologist 2020 Oct;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-10-26 / Oncologist 2020 Oct;2020-10-26 00:00:002020-10-26 00:00:00Emerging Immunotherapies in the Treatment of Brain Metastases
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-08-07 / Cancer Cell Int. 2020;20:380
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-08-07 / Cancer Cell Int. 2020;20:3802020-08-07 00:00:002020-08-07 00:00:00Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-21 / J Control Release 2020 Jun;326:63-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-21 / J Control Release 2020 Jun;326:63-742020-06-21 00:00:002020-06-21 00:00:00Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-12 / Front Oncol 2020;10:343
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-12 / Front Oncol 2020;10:3432020-03-12 00:00:002020-03-12 00:00:00Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-01 / J Immunother Cancer 2020 02;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-01 / J Immunother Cancer 2020 02;8(1)2020-02-01 00:00:002020-02-01 00:00:00TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-10-24 / Immunology 2020 01;159(1):75-87
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-10-24 / Immunology 2020 01;159(1):75-872019-10-24 00:00:002019-10-24 00:00:00Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine
